Hem/Onc Board Review

Hematology/oncology board review style questions. By @ahmadalhader and @DrM_AbuZaid

[Omar Abu Ghanimeh @omarabughanimeh]

Proud to be an investigator in the head and neck cohort of SGN35-033. Our data was discussed today at @ASCO, showing promising clinical efficacy of BV + Pembro in treatment -naive patients with metastatic HNSCC and CPS ≥1.

https://t.co/bz3Cj1ZDvp

@NebraskaMed @UNMCHemeOnc

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

Congrats to chief fellow @Noah_Onc for their @ConquerCancerFd Young Investigator Award investigating novel prostate cancer therapeutics and our brilliant faculty member @drshieldsmd Career Development Award in lung cancer. #ASCO2025 is off to a great start! @IUCancerCenter

[TwoOncDocs @TwoOncDocs]

Thank you all who joined Clinicals to Exams & guest appearance w/ baby Cary

A few high-yield mnemonics:
🌟 ribociclib - “ribs” close to ❤️- Qtc; abemaciclib - “abs” - diarrhea
🌟 tumor marker half-life: Hcg -3 letters, 1-3d; AFP -alpha - 5 letters 5-7d

Ready for #ASCO25 day 1!

[TwoOncDocs @TwoOncDocs]

This week’s episode we discussed our favorite heme/onc board review resources - books, Qbanks, podcasts ect 📕 🖥️ 🎙️

https://t.co/gEBjcSx9ta

[Hem/Onc Board Review @Hemoncq]

@DrChoueiri @myESMO @OncoAlert @TheLancet @Uromigos @brian_rini @montypal @AlbigesL @motzermd Some wishful thinking. But do you think the type of progression on IO matters?

Primary resistance vs secondary resistance? Slow progression with no new sites vs more rapid progression with new sites of disease? Mets location: lung vs other immunoresistant sites like liver?

[Hem/Onc Board Review @Hemoncq]

@brian_rini But low blow to mention reimbursement rates for IO here

It is ineffective but most of the use is due to wishful thinking and wanting to help rather than financial and malicious

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

Our fellow @AhmedBilalKhal2 recently attended the ASCR/ASCO Methods in Clinical Cancer Research Workshop to continue developing a clinical trial with our excellent GU faculty. Way to go!

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

Our fellow @Noah_Onc attended the AACR Molecular Biology in Clinical Oncology workshop, focused on molecular biology, translational cancer research, career development, and grant writing for the aspiring physician-scientist. Congrats!
@IUCancerCenter

[Hem/Onc Board Review @Hemoncq]

Great opportunity. One of 6 combined programs in the country! Facilitated by @ASCO

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

We are still accepting applications for our combined Hem/Onc & Palliative/Hospice medicine fellowship. It is a 3 year program eligible for the Hematology, Medical Oncology and Palliative Care boards.
@ASCO @IUHPMFellows
https://t.co/gqrXvLNE5e

[Hem/Onc Board Review @Hemoncq]

Definitely! For the boards, you don’t necessarily need to know the studies or the actual evidence (for the most part). You need to know first line, second line tx, etc

[Jennifer A. Marks, MD @jennifermarksmd]

To my friends studying for boards, I highly recommend downloading the @ASCO #guidelines app. @ASCOTECAG
Also -here are some excellent #Ovariancancer algorithms. @ABIMcert #gynsm #MedTwitter #OncTwitter
https://t.co/22frpHxhdn

[TwoOncDocs @TwoOncDocs]

We are back this week with @tompowles1 & @brian_rini diving into metastatic RCC!

We discuss risk stratification, their differing opinions around cytoreductive nephrectomy, 1L tx & sequencing, pearls regarding sarcomatoid, non-clear-cell RCC & tips for trainees @Uromigos

[Hem/Onc Board Review @Hemoncq]

@EladSharonMD @thenasheffect @ADesaiMD @MyriamChalabi @DrJNaidoo @drbrucejohnson @gulleyj1 @SashaGusevPosts @VivekSubbiah @tmprowell @jitcancer @eaonc I’ll double down and ask about melanoma. Present in < 1% as well

If I get an MSI-hi melanoma, would it tempt me to give single agent anti-PD1? Risk for undertreating?

Agree with the sentiment of checking MSI on all solid tumors, especially when ICIs aren’t part of 1st line tx

[Hem/Onc Board Review @Hemoncq]

@pashtoonkasi @fernandbteich @agrothey @HKennecke @FightCRC @CCAlliance @marklewismd @ShaalanBeg @cancerassassin1 @DocDustyD @mtmdphd @PresOnc_Connect @NTRKers @OncLive @VivekSubbiah Pashtoon, what do you do with MSI-H, braf-V600 post progression on Pembro?

I generally give Ipi/Nivo a try for 3 months. Then BEACON. Then chemo + Bev

Does it make a difference if primary or secondary resistance to Pembro?

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

We are very excited to welcome our new class of fellows matched @IUHemOnc
Congratulations! We are THRILLED to have you join us and looking forward to welcoming all of you! @IUCancerCenter

[Hem/Onc Board Review @Hemoncq]

@JackWestMD @SuyogCancer @PatelOncology @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert 💯

[Hem/Onc Board Review @Hemoncq]

@SuyogCancer @PatelOncology @JackWestMD @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert Who is coming up with this misleading 23%

A good 30% or so never progressed and didn’t need to be on Osi

[Ziad Bakouny, MD, MSc @ZiadBakouny]

Now @DrRoyHerbstYale with the third presentation of the plenary session with the #ADAURA study.

Now with an overall survival benefit with osimertinib in patients with EGFR+ NSCLC.
@ASCO #ASCO23

@YaleCancer @YaleMed @IMG_Oncologists @OncoAlert @HemOncToday @HemOncFellows @Hemoncq

[Hem/Onc Board Review @Hemoncq]

@ZiadBakouny @MSK_DeptOfMed @ASCO @MSKCancerCenter @OncoAlert @HemOncToday @HemOncFellows @DrChoueiri @eddy_saad @Chrislabaki1 @ReneeSaliby @TarekHaykal1 @NazliDizman @KarlSemaan @neerajaiims Looking forward to the discussion

Radiation free PROSPECT regimen vs the newer total neoadjuvant regimens with short course radiation

[Ziad Bakouny, MD, MSc @ZiadBakouny]

My future boss @MSK_DeptOfMed, Dr. Deborah Schrag, now taking the stage to present the results of the PROSPECT trial evaluating chemoradiation vs FOLFOX for locally advanced rectal cancer.
@ASCO #ASCO23

@MSKCancerCenter @OncoAlert @HemOncToday @HemOncFellows @Hemoncq

[Eric K. Singhi, MD @lungoncdoc]

☣️ Rare but life-threatening irAEs can have a lasting impact on our patients.

#OncTwitter, how do you strike a balance between effectively obtaining IO consent & communicating potential serious irAEs to patients without undue distress? @JackWestMD @DrJNaidoo @jillfeldman4